Nalm-6 CDX Model

Synonyms: OCI-AML-2

The Nalm-6 cell line is derived from human acute lymphoblastic leukemia (ALL), a malignancy characterized by an overproduction of immature white blood cells in the bone marrow. ALL is known for its rapid progression and its predilection for infiltrating the bone marrow, thus displacing healthy cells. The Nalm-6 cell line offers a comprehensive platform for understanding the underlying molecular mechanisms, progression, and potential therapeutic avenues of ALL. Representing key molecular and genetic traits common in ALL patients, Nalm-6 stands as an instrumental model for preclinical studies. The in vitro and in vivo behavior of Nalm-6 provides valuable insights into the growth dynamics of leukemia cells, their interaction with the bone marrow environment, and their response to various therapeutic agents. Researchers extensively use Nalm-6 to delve into the pathogenesis of ALL, evaluate the efficacy of novel treatments, and to gain insights into potential mechanisms of drug resistance in leukemia.

Model Details

Cancer Location: Intravenous
Cancer Type: Acute Lymphoblastic Leukemia
Model Name: Nalm-6
Mouse Strain: Nu/J
Treatment Data Available: Chemotherapy (Venetoclax, 5-Aza)

OCI-AML-2 Growth Curves

Nalm-6 CDX Model

Growth of subcutaneous OCI-AML-2 in Nu/J mice (n=10)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.